InstaCare Announces Receipt of Technology and Patent Value Analysis Penned by Joseph Wolf, Ph.D and William Walling, CFA

LOS ANGELES, March 2, 2011 /PRNewswire/ -- InstaCare Corp. (OTC Bulletin Board: ISCR) a leading provider of prescription and non-prescription diagnostics, home testing products for the chronically ill, a leading fulfillment provider of direct to patient diabetes programs, and a leading developer of revolutionary cell phone centric e-health products and technologies, today announced that the company's Board of Directors has received a patent and technology valuation report  from Joseph Wolf, Ph.D  and William N. Walling, Jr., CFA.  This report covers in detail the valuation of the company's MD@Hand™ and MD@Work™ technologies, for which a patent was recently filed. Additional patent filings are expected shortly.  The value analyses penned by Dr. Wolf and Mr. Walling are believed to be a major component of the company's planned application for listing on theNYSE:Amex.  The summary report is currently available for viewing on the company's website www.instacare.net.

Dr. Wolf, a clinical pharmacist, pharmacy doctor and long time expert in medical IT software and systems, and Mr. Walling, an expert financial analyst specializing in the domestic healthcare paradigm, were contracted to review the company's patent application, the value in use of the company's technologies and to assist the company as it monetizes the advantage of being first to market with proprietary and patent protected EMR/EHR mobile technology .

Keith Berman, Secretary and CFO of InstaCare Corp., commented:  "The Wolf and Walling report reinforces our long held belief that the company's MD@Hand and MD@Work products, which are based on our smart cell phone technologies, allow us to immediately secure strategic partners who have been clamoring for our products. This report concerning our patent and technology overview should assure the investment community and company's shareholders that management and the BOD have faithfully executed the tasks documented in our plans."

For more information about InstaCare Corp., Pharma Tech Solutions, Inc., or the Genstrip and/or its revolutionary MD@Hand or MD@Work cell phone centric technologies, please visit the InstaCare web site www.instacare.net or call the company at (805) 446-2973. If you do not have an Internet connection that will allow you to read and print the Technology and Patent Valuation Report, then please send an email to [email protected].  Include your name and address and a copy of the report will be mailed to you.

Forward-Looking Statements:

Forward-looking statements are statements made herein which do not address historical facts and, therefore could be interpreted to be forward-looking statements.  We can give no assurance that the expectations indicated by such forward-looking statements will be realized. There may be other risks and circumstances that we are unable to predict. When used in this release, words such as "believes," "expects," "forecasts," "intends," "projects," "plans," "anticipates," "estimates" and similar expressions are intended to identify forward-looking statements, although there may be certain statements not accompanied by such expressions. All forward-looking statements are intended to be covered by the safe harbor created by Section 21E of the Securities Exchange Act of 1934.  Such statements are subject to factors that could cause actual results to differ materially from anticipated results. The forward-looking statements included in this press release represent our views as of March 2, 2011.  We anticipate that subsequent events and developments will cause our views to change.

SOURCE InstaCare Corp.